Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

1.

Co-expression of MYC and BCL2 predicts poorer outcomes for relapsed/refractory diffuse large B-cell lymphoma with R-ICE and intent to transplant.

Allen J, Ruano Mendez AL, Rybicki L, Sawalha Y, Jagadeesh D, Dean R, Pohlman B, Smith MR, Hsi ED, Hill BT.

Ther Adv Hematol. 2018 Apr;9(4):81-87. doi: 10.1177/2040620718759249. Epub 2018 Mar 29.

2.

A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma.

Robertson MJ, Stamatkin CW, Pelloso D, Weisenbach J, Prasad NK, Safa AR.

J Immunother. 2018 Apr;41(3):151-157. doi: 10.1097/CJI.0000000000000220.

PMID:
29517616
3.

A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.

Foss FM, Parker T.

Oncologist. 2018 Apr;23(4):397-e30. doi: 10.1634/theoncologist.2017-0658. Epub 2018 Feb 7.

5.

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY.

N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.

PMID:
29226797
6.

Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma.

Myers RM, Hill BT, Shaw BE, Kim S, Millard HR, Battiwalla M, Majhail NS, Buchbinder D, Lazarus HM, Savani BN, Flowers MED, D'Souza A, Ehrhardt MJ, Langston A, Yared JA, Hayashi RJ, Daly A, Olsson RF, Inamoto Y, Malone AK, DeFilipp Z, Margossian SP, Warwick AB, Jaglowski S, Beitinjaneh A, Fung H, Kasow KA, Marks DI, Reynolds J, Stockerl-Goldstein K, Wirk B, Wood WA, Hamadani M, Satwani P.

Cancer. 2018 Feb 15;124(4):816-825. doi: 10.1002/cncr.31114. Epub 2017 Nov 10.

PMID:
29125192
7.

Artemether suppresses cell proliferation and induces apoptosis in diffuse large B cell lymphoma cells.

Zhao X, Guo X, Yue W, Wang J, Yang J, Chen J.

Exp Ther Med. 2017 Nov;14(5):4083-4090. doi: 10.3892/etm.2017.5063. Epub 2017 Aug 29.

8.

Prognostic analysis of DLBCL patients and the role of upfront ASCT in high-intermediate and high-risk patients.

Zhao Y, Wang H, Jin S, Zheng J, Huang M, Tang Y, Jin Z, Qiu H, Tang X, Fu C, Han Y, Wu DP.

Oncotarget. 2017 Apr 21;8(42):73168-73176. doi: 10.18632/oncotarget.17324. eCollection 2017 Sep 22.

9.

Evaluation of Lymphoma Patients Receiving High-Dose Therapy and Autologous Stem Cell Transplantation: Experience of a Single Center.

Bozkaya Y, Uncu D, Dağdaş S, Erdem GU, Doğan M, Özet G, Zengin N.

Indian J Hematol Blood Transfus. 2017 Sep;33(3):361-369. doi: 10.1007/s12288-016-0756-x. Epub 2016 Nov 29.

PMID:
28824238
10.

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.

Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek J, Go WY, Gisselbrecht C.

Blood. 2017 Oct 19;130(16):1800-1808. doi: 10.1182/blood-2017-03-769620. Epub 2017 Aug 3. Erratum in: Blood. 2018 Feb 1;131(5):587-588.

11.

Return to work for patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation.

Arboe B, Olsen MH, Goerloev JS, Duun-Henriksen AK, Johansen C, Dalton SO, Brown PN.

Clin Epidemiol. 2017 Jun 6;9:321-329. doi: 10.2147/CLEP.S134603. eCollection 2017.

12.

Liquid Chromatography Mass Spectrometry-Based Metabolite Pathway Analyses of Myeloma and Non-Hodgkin's Lymphoma Patients.

Medriano CAD, Na J, Lim KM, Chung JH, Park YH.

Cell J. 2017 Spring;19(Suppl 1):44-54. doi: 10.22074/cellj.2017.4412. Epub 2017 May 17.

13.

Genetic background and evolution of relapses in aggressive B-cell lymphomas.

Juskevicius D, Dirnhofer S, Tzankov A.

Haematologica. 2017 Jul;102(7):1139-1149. doi: 10.3324/haematol.2016.151647. Epub 2017 May 29. Review.

14.

A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.

Srour SA, Li S, Popat UR, Qazilbash MH, Lozano-Cerrada S, Maadani F, Alousi A, Kebriaei P, Anderlini P, Nieto Y, Jones R, Shpall E, Champlin RE, Hosing C.

Br J Haematol. 2017 Aug;178(4):561-570. doi: 10.1111/bjh.14731. Epub 2017 May 9.

15.

A Review of Autologous Stem Cell Transplantation in Lymphoma.

Zahid U, Akbar F, Amaraneni A, Husnain M, Chan O, Riaz IB, McBride A, Iftikhar A, Anwer F.

Curr Hematol Malig Rep. 2017 Jun;12(3):217-226. doi: 10.1007/s11899-017-0382-1. Review.

PMID:
28478586
16.

Indian Council of Medical Research Consensus Document for the Management of Non-Hodgkin's Lymphoma (High Grade).

Doval DC, Bhurani D, Nair R, Gujral S, Malhotra P, Ramanan G, Mohan R, Biswas G, Dattatreya S, Agarwal S, Pendharkar D, Julka PK, Advani SH, Dhaliwal RS, Tayal J, Sinha R, Kaur T, Rath GK.

Indian J Med Paediatr Oncol. 2017 Jan-Mar;38(1):51-58. doi: 10.4103/0971-5851.203500. Review.

17.

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma.

Mehrzad V, Ashrafi F, Farrashi AR, Pourmarjani R, Dehghani M, Shahsanaei A.

Adv Biomed Res. 2017 Mar 7;6:30. doi: 10.4103/2277-9175.201687. eCollection 2017.

18.

The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.

Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Champlin RE, Andersson BS.

Leuk Lymphoma. 2017 Nov;58(11):2705-2716. doi: 10.1080/10428194.2017.1306647. Epub 2017 Apr 10.

PMID:
28394191
19.

Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology.

Krishnan AY, Palmer J, Nademanee AP, Chen R, Popplewell LL, Tsai NC, Sanchez JF, Simpson J, Spielberger R, Yamauchi D, Forman SJ.

Biol Blood Marrow Transplant. 2017 Jun;23(6):922-929. doi: 10.1016/j.bbmt.2017.03.004. Epub 2017 Mar 4.

PMID:
28267593
20.

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.

Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, Merryman RW, Bedell V, Pak C, Sun H, Paris T, Stiller T, Brown JR, Budde LE, Chan WC, Chen R, Davids MS, Freedman AS, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce AS, Murata-Collins J, Nademanee AP, Palmer JM, Pihan GA, Pillai R, Popplewell L, Siddiqi T, Sohani AR, Zain J, Rosen ST, Kwak LW, Weinstock DM, Forman SJ, Weisenburger DD, Kim Y, Rodig SJ, Krishnan A, Armand P.

J Clin Oncol. 2017 Jan;35(1):24-31. Epub 2016 Oct 24.

Supplemental Content

Support Center